Stuart J Kahn
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$9.6MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $9.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 10, 2021 | NIH | SBIR Phase II A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | $651K | Syntrix Biosystems, Inc. |
| May 27, 2021 | NIH | SBIR Phase II A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | $80K | Syntrix Biosystems, Inc. |
| Sep 4, 2020 | NIH | SBIR Phase II HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | $1.6M | Syntrix Biosystems, Inc. |
| Jun 11, 2020 | NIH | SBIR Phase II A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | $223K | Syntrix Biosystems, Inc. |
| Mar 31, 2020 | NIH | SBIR Phase II A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | $1.2M | Syntrix Biosystems, Inc. |
| May 7, 2019 | NIH | SBIR Phase II A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects | $204K | Syntrix Biosystems, Inc. |
| Aug 24, 2018 | NIH | SBIR Phase II HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients | $398K | Syntrix Biosystems, Inc. |
| Aug 14, 2018 | NIH | SBIR Phase II Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine | $977K | Syntrix Biosystems, Inc. |
| Jul 27, 2017 | NIH | SBIR Phase II Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine | $998K | Syntrix Biosystems, Inc. |
| Jul 12, 2017 | NIH | SBIR Phase II Phase II clinical evaluation of Omnitram in neuropathic pain | $657K | Syntrix Biosystems, Inc. |
| May 4, 2017 | NIH | SBIR Phase II A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma | $621K | Syntrix Biosystems, Inc. |
| Aug 22, 2016 | NIH | SBIR Phase II Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine | $990K | Syntrix Biosystems, Inc. |
| Jul 18, 2016 | NIH | SBIR Phase II Phase II clinical evaluation of Omnitram in neuropathic pain | $843K | Syntrix Biosystems, Inc. |
| Jul 21, 2015 | NIH | SBIR Phase II Phase II clinical evaluation of Omnitram in neuropathic pain | $225K | Syntrix Biosystems, Inc. |
Peer ranks
Federal funding#65
Awards as PI#57
Patents#273
Companies
- Syntrix Biosystems, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.